10 May 2017 in Journal of the Chinese Medical Association
Superior vena cava (SVC) syndrome comprises a group of signs and symptoms secondary to SVC obstruction. Obstruction occurs when venous return from the SVC to the right atrium is compromised, mostly by a growing malignancy compressing the SVC extrinsically.1, 2, 3, 4, 5 In the absence of adequate collaterals, the resulting elevated venous pressure in the upper body leads to edema of the head, neck, and upper extremities. Rarely, swelling of the larynx may cause life-threatening airway obstruction and cerebral edema, which can result in confusion and coma. While treatment of underlying malignant disease is paramount, it may be slow to alleviate the patient's discomfort. In some radiosensitive malignancies, radiotherapy may effectively reduce symptoms by reducing the tumor size,3, 6 but this process can take weeks to months and has a higher recurrence rate. The increasing technical and clinical success rate of SVC stenting makes it another option for salvage therapy after conventional radiochemotherapy has failed. In fact, Ganeshan et al. suggested that primary SVC stenting should be the first-line treatment to relieve the symptoms of SVC syndrome.4 The aim of the present study was to review our SVC stenting experience retrospectively in order to validate the safety, effectiveness, and outcomes of salvage and primary stenting for malignant SVC obstruction.
1 March 2005 in Diamond and Related Materials
29 January 2022 in Journal of the Formosan Medical Association
Data about volumetric remodeling of the provisional extension to induce complete attachment (PETTICOAT) technique on DeBakey type IIIb aortic dissection in acute and subacute phases were scarce. The proper timing to perform this technique to promote false lumen reduction was also unknown. Patients with DeBakey type IIIb aortic dissection who underwent the PETTICOAT technique between December 2005 and March 2017 were reviewed and divided into acute (treatment occurred ≦14 days after symptom onset) and subacute (15-90 days) groups. Remodeling parameters of the true and false lumens were analyzed. Receiver operating characteristic curve was used to deduce the timing of this technique. In the 2-year follow-up, the acute group (N = 20) demonstrated significant true lumen expansion and false lumen regression in the thoracic, abdominal, and total aorta. However, the subacute group (N = 20) only showed significant shrinkage in the false lumen of the thoracic and total aorta. Using PETTICOAT technique within 36 days after the aortic event may result in better total false lumen reduction. For DeBakey type IIIb aortic dissection, more prominent true lumen expansion and false lumen reduction were noted when using the PETTICOAT technique in the acute phase. When performed within 36 days after symptoms onset, the PETTICOAT technique may potentiate better total false lumen regression.
21 December 2020 in Interactive CardioVascular and Thoracic Surgery
OBJECTIVES: Although commercial iliac branch devices offer a new and valid endovascular approach to treating iliac aneurysm and effectively preserve antegrade flow of the internal iliac artery, their use may not be suited for all types of challenging anatomy, especially isolated common iliac artery aneurysm. Our custom-made iliac bifurcation device has a unique design and excludes both combined and isolated iliac branch aneurysm. This study validated the efficacy and safety of the custom device by comparing clinical outcomes between groups receiving commercial and custom devices. METHODS: Data of consecutive patients receiving iliac bifurcation device implantation for iliac aneurysm with or without concomitant endovascular repair for abdominal aortic aneurysm from January 2010 to May 2019 were reviewed. RESULTS: Iliac bifurcation device implantation with or without concomitant abdominal aortic aneurysm stent grafting was completed in 46 patients (commercial, n = 35; custom, n = 11). No significant differences were observed regarding postoperative complications, occlusion or endoleak. Comparisons of primary (80.8% vs 85.7%, P = 0.88) and secondary (86.5% vs 85.7%, P = 0.85) patency and freedom from reintervention (88.2% vs 100%, P = 0.33), all-cause mortality (78.6% vs 100%, P = 0.25) and aneurysm-related mortality (100% vs 100%, P = 1.00) also indicated no differences at a 5-year surveillance point. Furthermore, the iliac aneurysms of the groups displayed similar shrinkage 1 year after procedures. CONCLUSIONS: For iliac aneurysm, the novel custom-made iliac bifurcation device is an adaptable design not inferior to commercial devices with regard to postoperative complications, bridge occlusion, endoleak and short-term aneurysm remodelling. It provides an alternative for treatment, particularly when certain anatomic challenges are present. Clinical trial registration: 2018-07-050BC, 2017-01-023ACF.
22 July 2017 in Annals of Vascular Surgery